NCT04526210View on ClinicalTrials.gov

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions
Wilson Disease
Interventions
DRUG

ALXN1840

ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.

DRUG

Bupropion Hydrochloride

Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).

Trial Locations (1)

78744

Clinical Trial Site, Austin

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY